Similar articles

• Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

  Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Harrison CN, et al. N Engl J Med. 2005 Jul 7;353(1):33-45. doi: 10.1056/NEJMoa043800. N Engl J Med. 2005. PMID: 16000354 Clinical Trial.
• [Treatment of essential thrombocythemia].

  Alvarez-Larrán A, Cervantes F, Besses C. Alvarez-Larrán A, et al. Med Clin (Barc). 2013 Sep 21;141(6):260-4. doi: 10.1016/j.medcli.2013.01.016. Epub 2013 Mar 13. Med Clin (Barc). 2013. PMID: 23490491 Review. Spanish.
• Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.

  Cacciola RR, Di Francesco E, Pezzella F, Tibullo D, Giustolisi R, Cacciola E. Cacciola RR, et al. Acta Haematol. 2007;118(4):215-8. doi: 10.1159/000111776. Epub 2007 Nov 29. Acta Haematol. 2007. PMID: 18057866 Clinical Trial. No abstract available.
• The pathogenesis and management of essential thrombocythaemia.

  Green AR. Green AR. Haematologica. 1999 Jun;84 Suppl EHA-4:36-9. Haematologica. 1999. PMID: 10907463 Review. No abstract available.
• Anagrelide: what was new in 2004 and 2005?

  Petrides PE. Petrides PE. Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):399-408. doi: 10.1055/s-2006-942760. Semin Thromb Hemost. 2006. PMID: 16810615 Review.